Moreover, therapeutic targeting of the oxidative phosphorylation pathway with IACS-10759 or of glutamine metabolism with glutaminase inhibitor CB839 in mouse models of melanoma BrM improved survival and reduced BrM burden [20, 22]. Here, GLS is linked to melanoma.